Neutralizing IFN-γ enhanced inflammatory lymphangiogenesis regardless of VEGF-A and VEGF-C levels, while blocking Th2 cytokines, IL-4 and IL-13, reduced lymphedema and improved lymphatic function [58]. The gene discussed is IL13; the disease is lymphedema.